The Annual Blood-Brain Barrier Consortium Meeting

描述（由申请人提供）：第十一届年度血脑屏障联盟会议定于2005年3月17日至19日在波特兰或。 会议的总体假设是，在CNS恶性肿瘤和神经系统疾病中增加治疗药物的递送可以改善生存率和生活质量，而不会增加全身或神经系统毒性。 会议的目标是回顾BBB，脑肿瘤和神经系统疾病的基础科学，临床前和临床研究。 每次会议都会聚焦研究进展可能影响大脑交付，成像或治疗的新领域。2005年会议的科学会议主题将是1）细胞和分子成像，2）纳米技术和纳米医学，3）化学保护。 每次会议的一半时间用于制定新的临床方案。 2005年，临床会议将集中在1）临床方案开发，以增加对原发性和转移性脑肿瘤的治疗，2）化学保护，3）恶性脑肿瘤和中枢神经系统病变的磁共振成像。 在之前的会议上，已经发表了五篇关于神经肿瘤临床试验中剂量强度与神经毒性、原发性和转移性脑肿瘤靶向给药以及预防毒性策略的出版物。 鼓励来自BBB联盟参与机构的主要研究者、临床工作人员和研究人员参加年度BBB会议。 邀请杰出的科学家参加，以及来自OHSU，NIH和其他大学的临床医生和研究人员参加BBB和神经肿瘤学研究项目，特别强调转化研究。 我们鼓励和招募少数民族、妇女和残疾临床医生和科学家的参与。 2005年BBB会议将继续为BBB联盟提供一个论坛，以满足研究人员，临床前研究转化为临床，并制定多中心协议，以确定化学敏感性脑肿瘤的最佳治疗策略。

DESCRIPTION (provided by applicant): The Eleventh Annual Blood-Brain Barrier Consortium Meeting is scheduled for March 17-19, 2005, in Portland OR. The overall hypothesis of the meeting is that increased delivery of therapeutics in CNS malignancy and neurological diseases can improve survival and quality of life without increased systemic or neurological toxicity. The goals of the meeting are to review basic science, preclinical, and clinical research on the BBB, brain tumors, and neurological diseases. Every meeting spotlights new areas in which research advances may impact brain delivery, imaging, or therapy. The scientific session topics for the 2005 meeting will be 1) Cell and Molecular imaging, 2) Nanotechnology and nanomedicine, and 3) Chemoprotection. Half of each meeting is devoted to the development of new clinical protocols. In 2005, the clinical sessions will concentrate on 1) clinical protocol development to increase delivery to primary and metastatic brain tumors, 2) Chemoprotection, and 3) MR imaging of malignant brain tumors and CNS lesions. Five publications have been developed from previous meetings regarding dose intensity versus neurotoxicity in neuro-oncology clinical trials, targeted delivery in primary and metastatic brain tumors, and strategies for prevention of toxicity. Attendance at the annual BBB meeting is encouraged for principal investigators, clinical staff, and researchers from the participating institutions of the BBB Consortium. Distinguished scientists are invited to attend, as well as clinicians and researchers from OHSU, NIH, and other universities with research programs in the BBB and neuro-oncology, with a particular emphasis on translational research. We encourage and recruit the participation of minority, women and disabled clinicians and scientists. The 2005 BBB meeting will continue to provide a forum for the BBB Consortium to meet fellow researchers, translate preclinical research to the clinic, and develop multi-center protocols to determine optimal treatment strategies for chemo-sensitive brain tumors.